{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T17:41:08Z","timestamp":1788716468210,"version":"build-2803163510"},"reference-count":52,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2008,8,1]],"date-time":"2008-08-01T00:00:00Z","timestamp":1217548800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,8,1]],"date-time":"2008-08-01T00:00:00Z","timestamp":1217548800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2008,8]]},"DOI":"10.1016\/j.jaad.2008.03.023","type":"journal-article","created":{"date-parts":[[2008,5,16]],"date-time":"2008-05-16T13:05:34Z","timestamp":1210943134000},"page":"209-217","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":138,"title":["National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents"],"prefix":"10.1016","volume":"59","author":[{"given":"Sean D.","family":"Doherty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abby","family":"Van Voorhees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark G.","family":"Lebwohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil J.","family":"Korman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melodie S.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2008.03.023_bib1","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/S0140-6736(00)04954-0","article-title":"Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial","volume":"357","author":"Chaudhari","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2008.03.023_bib2","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1001\/archderm.139.12.1627","article-title":"A randomized trial of etanercept as monotherapy for psoriasis","volume":"139","author":"Gottlieb","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2008.03.023_bib3","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/j.1365-2133.2007.08315.x","article-title":"Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION)","volume":"158","author":"Saurat","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2008.03.023_bib4","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jaad.2007.09.010","article-title":"Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial","volume":"58","author":"Menter","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2008.03.023_bib5","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/art.10671","article-title":"Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurements of reduction of inflammation","volume":"47","author":"Antoni","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2008.03.023_bib6","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(00)02530-7","article-title":"Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial","volume":"356","author":"Mease","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2008.03.023_bib7","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1002\/art.21306","article-title":"Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial","volume":"52","author":"Mease","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2008.03.023_bib8","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1016\/j.jaad.2006.07.019","article-title":"Off-label uses of biologics in dermatology: rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (part 2 of 2)","volume":"56","author":"Graves","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2008.03.023_bib9","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0923-2494(97)85223-6","article-title":"The role of cytokines in the immune response to tuberculosis","volume":"147","author":"Kaplan","year":"1996","journal-title":"Res Immunol"},{"key":"10.1016\/j.jaad.2008.03.023_bib10","doi-asserted-by":"crossref","first-page":"S221","DOI":"10.1164\/ajrccm.161.supplement_3.ats600","article-title":"Targeted tuberculin testing and treatment of latent tuberculosis infection","volume":"161","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaad.2008.03.023_bib11","doi-asserted-by":"crossref","first-page":"4195","DOI":"10.1128\/IAI.69.7.4195-4201.2001","article-title":"Tuberculosis: latency and reactivation","volume":"69","author":"Flynn","year":"2001","journal-title":"Infect Immun"},{"key":"10.1016\/j.jaad.2008.03.023_bib12","first-page":"1","article-title":"Controlling tuberculosis in the United States. Recommendations from the American Thoracic Society, CDC, and the Infectious Diseases Society of America","volume":"54","author":"Taylor","year":"2005","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.jaad.2008.03.023_bib13","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/jlb.49.4.380","volume":"49","author":"Denis","year":"1991","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.jaad.2008.03.023_bib14","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/0092-8674(89)90676-4","article-title":"The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection","volume":"56","author":"Kindler","year":"1989","journal-title":"Cell"},{"key":"10.1016\/j.jaad.2008.03.023_bib15","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1002\/art.11301","article-title":"Infections and anti-tumor necrosis factor alpha therapy","volume":"48","author":"Ellerin","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2008.03.023_bib16","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2008.03.023_bib17","first-page":"292","article-title":"The comparative safety and effectiveness of TNF-alpha antagonists [corrected] J Manag Care Pharm 2s007;13:S7-18","volume":"13","author":"Solomon","year":"2007","journal-title":"Erratum in"},{"key":"10.1016\/j.jaad.2008.03.023_bib18","series-title":"Remicade (infliximab) for IV injection: prescribing information","year":"2006"},{"key":"10.1016\/j.jaad.2008.03.023_bib19","unstructured":"Humira (adalimumab) for subcutaneous injection: prescribing information. North Chicago (IL): Abbot Biotechnology. Available at: http:\/\/www.fda.gov\/cder\/foi\/label\/2002\/adalabb123102LB.pdf Accessed August 11, 2007."},{"key":"10.1016\/j.jaad.2008.03.023_bib20","unstructured":"CDC. Guide for primary health care providers: targeted tuberculin testing and treatment of latent tuberculosis infection. Available at: www.cdc.gov\/tb\/pubs\/LTBI\/pdf\/TargetedLTBI05.pdf. Accessed January 2, 2008."},{"key":"10.1016\/j.jaad.2008.03.023_bib21","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S1473-3099(03)00545-0","article-title":"Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management","volume":"3","author":"Gardam","year":"2003","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jaad.2008.03.023_bib22","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1136\/bmj.318.7183.593","article-title":"Clinical guidelines: developing guidelines","volume":"318","author":"Shekelle","year":"1999","journal-title":"BMJ"},{"key":"10.1016\/j.jaad.2008.03.023_bib23","first-page":"683","article-title":"Tuberculosis associated with blocking agents against tumor necrosis factor-alpha\u2013California, 2002-2003","volume":"53","year":"2004","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jaad.2008.03.023_bib24","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1164\/ajrccm.161.4.16141","article-title":"Diagnostic standards and classification of tuberculosis in adults and children","volume":"161","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaad.2008.03.023_bib25","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/ncprheum0336","article-title":"Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor","volume":"2","author":"Winthrop","year":"2006","journal-title":"Nat Clin Pract Rheumatol"},{"key":"10.1016\/j.jaad.2008.03.023_bib26","first-page":"800","article-title":"BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment","volume":"6","year":"2005","journal-title":"Thorax"},{"key":"10.1016\/j.jaad.2008.03.023_bib27","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1002\/art.21382","article-title":"Tuberculosis associated with therapy against tumor necrosis factor alpha","volume":"52","author":"Winthrop","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2008.03.023_bib28","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S1473-3099(04)01206-X","article-title":"Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review","volume":"4","author":"Pai","year":"2004","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jaad.2008.03.023_bib29","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1136\/ard.2007.069799","article-title":"Comparison of in vitro-specific blood tests with tuberculin skin test for diagnosis of latent tuberculosis before anti-TNF therapy","volume":"66","author":"Sellam","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2008.03.023_bib30","first-page":"49","article-title":"Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States","volume":"54","author":"Mazurek","year":"2005","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.jaad.2008.03.023_bib31","first-page":"474","article-title":"Infliximab does not suppress the tuberculin skin test (purified protein derivative)","volume":"34","author":"Hatemi","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2008.03.023_bib32","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1136\/ard.2007.070789","article-title":"Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases performance of a mycobacterium tuberculosis antigen specific IFN-gamma assay","volume":"67","author":"Matulis","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2008.03.023_bib33","doi-asserted-by":"crossref","first-page":"iv29","DOI":"10.1136\/ard.2005.042390","article-title":"Update on tuberculosis and other opportunistic infections associated with drugs blocking tumour necrosis factor {alpha}","volume":"64","author":"Winthrop","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2008.03.023_bib34","first-page":"735","article-title":"Update: adverse event data and revised American Thoracic Society\/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection\u2013United States, 2003","volume":"52","year":"2003","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jaad.2008.03.023_bib35","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1086\/425610","article-title":"Use of intermittent rifampin and pyrazinamide therapy for latent tuberculosis infection in a targeted tuberculin testing program","volume":"39","author":"Priest","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jaad.2008.03.023_bib36","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1136\/ard.62.8.791","article-title":"French guidelines for diagnosis and treating latent and active tuberculosis in patients with RA treated with TNF blockers","volume":"62","author":"Mariette","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2008.03.023_bib37","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1002\/art.21043","article-title":"Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists","volume":"52","author":"Carmona","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2008.03.023_bib38","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1093\/rheumatology\/kel447","article-title":"Development of active tuberculosis following initiation of infliximab despite appropriate prophylaxis","volume":"46","author":"Raychaudhuri","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaad.2008.03.023_bib39","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/art.22768","article-title":"Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection","volume":"57","author":"Gomez-Reino","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2008.03.023_bib40","first-page":"1657","article-title":"Development of tuberculosis in a patient treated with infliximab who had received prophylactic therapy with isoniazid","volume":"30","author":"Parra Ruiz","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2008.03.023_bib41","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1124\/jpet.301.2.418","article-title":"Binding and functional comparisons of two types of tumor necrosis factor antagonists","volume":"301","author":"Scallon","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jaad.2008.03.023_bib42","series-title":"Enbrel (etanercept) for subcutaneous injection: prescribing information","year":"2003"},{"key":"10.1016\/j.jaad.2008.03.023_bib43","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1086\/424455","article-title":"Granulomatous infections due to tumor necrosis factor blockade: correction","volume":"39","author":"Wallis","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jaad.2008.03.023_bib44","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1002\/art.21386","article-title":"Infections in patients with rheumatoid arthritis treated with biologic agents","volume":"52","author":"Listing","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2008.03.023_bib45","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/j.1365-2133.1971.tb02548.x","article-title":"Psoriasis, methotrexate and tuberculosis","volume":"84","author":"Smith","year":"1971","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2008.03.023_bib46","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1093\/rheumatology\/37.10.1136","article-title":"Cavitary lung tuberculosis in a rheumatoid arthritis patient treated with low-dose methotrexate and steroid pulse therapy","volume":"37","author":"di Girolamo","year":"1998","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.jaad.2008.03.023_bib47","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/rheumatology\/40.3.341","article-title":"Late reactivation of spinal tuberculosis by low-dose methotrexate therapy in a patient with rheumatoid arthritis","volume":"40","author":"Binymin","year":"2001","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaad.2008.03.023_bib48","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1136\/ard.2002.004598","article-title":"High incidence of hepatotoxicity of isoniazid treatment for tuberculosis chemoprophylaxis in patients with rheumatoid arthritis treated with methotrexate or sulfasalazine and anti-tumour necrosis factor inhibitors","volume":"62","author":"Vanhoof","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2008.03.023_bib49","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1136\/ard.2007.076406","article-title":"Methotrexate combined with isoniazid therapy for latent tuberculosis is well tolerated in rheumatoid arthritis patients: experience from an urban arthritis clinic","volume":"67","author":"Mor","year":"2008","journal-title":"Ann Rheum"},{"key":"10.1016\/j.jaad.2008.03.023_bib50","first-page":"189","article-title":"Review of cyclosporine immunosuppressive safety data in dermatology patients after two decades of use","volume":"4","author":"Behnam","year":"2005","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2008.03.023_bib51","doi-asserted-by":"crossref","unstructured":"Vachharajani TJ, Oza UG, Phadke AG, Kirpalani AL. Tuberculosis in renal transplant recipients: rifampicin sparing treatment protocol. Int Urol Nephrol 2002-2003;34:551-3.","DOI":"10.1023\/A:1025693521582"},{"key":"10.1016\/j.jaad.2008.03.023_bib52","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jaad.2007.08.030","article-title":"From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis","volume":"58","author":"Lebwohl","year":"2008","journal-title":"J Am Acad Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962208003939?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962208003939?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:09:52Z","timestamp":1759270192000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962208003939"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,8]]}},"alternative-id":["S0190962208003939"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2008.03.023","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2008,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2008.03.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}